# EDGAR Filing Document

**Accession Number:** 0001802528
**File Stem:** 0001104659-25-085815
**Filing Date:** 2025-9
**Character Count:** 7772
**Document Hash:** b277035671cd4e5aaaa667954c24254b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-085815.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0001104659-25-085815

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250902

**EFFECTIVENESS DATE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fairmount Funds Management LLC
- **CENTRAL INDEX KEY:** 0001802528

**ORGANIZATION NAME:**
- **EIN:** 364841215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-19908
- **FILM NUMBER:** 251282343

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 267-262-5300

**MAIL ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001802528

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Fairmount Funds Management LLC

**Address:** 200 BARR HARBOR DRIVE, W CONSHOHOCKEN, PA 19428

**Telephone number:** 267-262-5300

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-19908

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 549300KMPFHUFJ6T6Y84

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                             | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                               | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Dianthus Therapeutics, Inc.                | 252828108 | 05/22/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers; and                                                   | SECTION 14A SAY-ON-PAY VOTES |      2.70069e+06 |                0 | FOR         |                              2.70069e+06 | FOR                         |  |
| SCHOLAR ROCK HOLDING CORPORATION           | 80706P103 | 05/22/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                      | SECTION 14A SAY-ON-PAY VOTES |      1.37403e+06 |                0 | FOR         |                              1.37403e+06 | FOR                         |  |
| Spyre Therapeutics, Inc.                   | 00773J202 | 05/29/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                      | SECTION 14A SAY-ON-PAY VOTES |      4.0181e+06  |                0 | FOR         |                              4.0181e+06  | FOR                         |  |
| Oruka Therapeutics, Inc.                   | 687604108 | 06/02/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                | SECTION 14A SAY-ON-PAY VOTES |      3.37192e+06 |                0 | FOR         |                              3.37192e+06 | FOR                         |  |
| Oruka Therapeutics, Inc.                   | 687604108 | 06/02/2025     | To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |      3.37192e+06 |                0 | ONE YEAR    |                              3.37192e+06 | FOR                         |  |
| Kiniksa Pharmaceuticals International, plc | G52694109 | 06/03/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                              | SECTION 14A SAY-ON-PAY VOTES |      1.3961e+06  |                0 | FOR         |                              1.3961e+06  | FOR                         |  |
| Cogent Biosciences, Inc.                   | 19240Q201 | 06/04/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                     | SECTION 14A SAY-ON-PAY VOTES |      6.22564e+06 |                0 | FOR         |                              6.22564e+06 | FOR                         |  |
| Axsome Therapeutics, Inc.                  | 05464T104 | 06/06/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                    | SECTION 14A SAY-ON-PAY VOTES | 815176           |                0 | FOR         |                         815176           | FOR                         |  |
| Astria Therapeutics, Inc.                  | 04635X102 | 06/11/2025     | The approval, by non-binding advisory vote, of our executive compensation.                                                                     | SECTION 14A SAY-ON-PAY VOTES |      3.55413e+06 |                0 | FOR         |                              3.55413e+06 | FOR                         |  |
| Apogee Therapeutics, Inc.                  | 03770N101 | 06/17/2025     | Vote on the frequency of future advisory votes to approve our named executive officers compensation.                                           | SECTION 14A SAY-ON-PAY VOTES |      2.04865e+06 |                0 | ONE YEAR    |                              2.04865e+06 | FOR                         |  |
| Nuvalent, Inc.                             | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                       | SECTION 14A SAY-ON-PAY VOTES | 727563           |                0 | FOR         |                         727563           | FOR                         |  |
| Viridian Therapeutics, Inc.                | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                  | SECTION 14A SAY-ON-PAY VOTES |      3.44581e+06 |                0 | FOR         |                              3.44581e+06 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Fairmount Funds Management LLC

**By (Signature):** Erin O'Connor

**By (Printed Signature):** Erin O'Connor

**By (Title):** Chief Compliance Officer

**Date:** 08/29/2025